Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment

Fig. 1

The manufacture and characterization of hUCMSC-EVs. a hUCMSC-EVs manufacturing process and critical quality control points (CQCP). UCMSCs were prepared from a working bank with culture for 4 passages (P4). CQCPs were performed at the different stages of the cell expansion and EV isolation. The final EVs were stored for the patient application with nebulizer. The major manufacturing parameters were labeled. This figure was created using MedPeer (www.medpeer.cn). b The concentration and size distribution of hUCMSC-EVs. hUCMSC-EVs were determined by Nanoparticle Tracking Analysis (NTA). The specific EV sizes were labeled. The distribution curve (black) was fit from the examined value (red). c Representative electron microscopic (EM) photograph of hUCMSC-EVs, scale bar=500 nm. hUCMSC-EVs were prepared for the image by EM. d Representative electron microscopic photographs of hUCMSC-EVs before and after nebulization. hUCMSC-EVs were collected from condensation after nebulization. scale bar = 100 nm. Levels of EV markers. Western blots were performed for the protein levels of EV marker including CD9 (e), CD63 (f), CD81 (g), and CANX (h). The EV marker alteration after nebulization. Western blots showed the protein markers in the hUCMSC-EVs before and after nebulization (Neb). CD81 (i), fibronectin (j), CD63 (k) and CD9 (l) were examined

Back to article page